[HTML][HTML] A phase 3b, open-label, single-arm, multicenter, expanded-access study of the safety and clinical outcomes of StrataGraft® treatment in adults with deep …

JH Holmes IV, ALF Gibson, T Short, VC Joe, J Litt… - Burns, 2024 - Elsevier
Background A phase 3b, open-label, multicenter, expanded-access study (NCT04123548)
evaluated safety and clinical outcomes of StrataGraft treatment in adults with deep partial …

Construction of an instrument to evaluate the quality of hospital care provided in burns units in Brazil: a Delphi study

DRR Suzuki, LA Santana, JEHG Ávila, FF Amorim… - Burns, 2024 - Elsevier
Background Providing excellent care to patients with acute burns can result in lower
mortality and disability in the long-term. There are no specific instruments to evaluate the …

Establishing Consensus of Best Practice for CEA Use in Treatment of Severe Burns: A US Burn Provider Delphi Study

P Glat, L Quirk, S Hultman, J Kesey… - Journal of Burn Care …, 2024 - academic.oup.com
The goal of this study was to inform standards of best practice in the use of cultured
epidermal autograft (CEA), manufactured in the United States, for the treatment of patients …

Defining a meaningful reduction of donor sites-Not as easy as it seems.

C Smolle, SP Nischwitz, LP Kamolz - Burns: Journal of the …, 2021 - europepmc.org
A comment on this article appears in" Donor site morbidity-Where is the evidence to guide
therapeutic decision making?" Burns. 2021 Sep; 47 (6): 1456-1457. This is a comment on" …

Avanços no Transplante de Pele em Pacientes Queimados: Estratégias Dermatológicas para Melhorar a Sobrevivência ea Função da Pele

MDA Azenha, BC Hirsch, HF Cruz… - Brazilian Journal of …, 2024 - bjihs.emnuvens.com.br
O tratamento de queimaduras graves exige uma abordagem abrangente que inclui
diagnóstico precoce, intervenções cirúrgicas precisas e cuidados pós-operatórios …

Donor site morbidity-Where is the evidence to guide therapeutic decision making?

CM Legemate, CH van der Vlies - Burns: journal of the …, 2021 - pubmed.ncbi.nlm.nih.gov
Donor site morbidity - Where is the evidence to guide therapeutic decision making? Donor site
morbidity - Where is the evidence to guide therapeutic decision making? Burns. 2021 …

[引用][C] Response to Letter to the Editor" Defining a meaningful reduction of donor sites-Not as easy as it seems".

ALF Gibson, J Smiell, TC Yu, EA Böing… - Burns: Journal of the …, 2021 - europepmc.org
This is a comment on" Determining clinically meaningful thresholds for innovative burn care
products to reduce autograft: A US burn surgeon Delphi panel." Burns. 2021 Aug; 47 (5) …